Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).
How is Esperion Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ESPR's short term assets ($253.5M) exceed its short term liabilities ($57.5M).
Long Term Liabilities: ESPR's short term assets ($253.5M) exceed its long term liabilities ($129.2M).
Debt to Equity History and Analysis
Debt Level: ESPR is debt free.
Reducing Debt: ESPR has no debt compared to 5 years ago when its debt to equity ratio was 9.6%.
Balance Sheet
Inventory Level: ESPR has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if ESPR's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ESPR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ESPR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -0.3% each year
What is Esperion Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate ESPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ESPR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ESPR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ESPR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ESPR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
What is the CEO of Esperion Therapeutics's salary, the management and board of directors tenure and is there insider trading?
1.7yrs
Average management tenure
CEO
TimMayleben(58yo)
7yrs
Tenure
US$9,724,839
Compensation
Mr. Timothy M. Mayleben, also known as Tim, M.B.A., has been the Chief Executive Officer and President of Esperion Therapeutics, Inc. since December 2012. Mr. Mayleben serves as an Advisor to several biote ...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD9.72M) is above average for companies of similar size in the US market ($USD3.89M).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
1.7yrs
Average Tenure
53yo
Average Age
Experienced Management: ESPR's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Age and Tenure
4.5yrs
Average Tenure
58yo
Average Age
Experienced Board: ESPR's board of directors are considered experienced (4.5 years average tenure).
Insider Trading
Insider Buying: ESPR insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
BuyUS$184,90008 Nov 19
Timothy Mayleben
Entity
Individual
Role
Chief Executive Officer
President
Shares
5,000
Max Price
US$36.98
BuyUS$2,797,56008 Nov 19
Bellevue Asset Management AG
Entity
Company
Shares
75,000
Max Price
US$37.30
BuyUS$259,10706 Sep 19
Timothy Mayleben
Entity
Individual
Role
Chief Executive Officer
President
Shares
7,500
Max Price
US$35.25
BuyUS$2,702,20806 Sep 19
Bellevue Asset Management AG
Entity
Company
Shares
80,000
Max Price
US$33.78
BuyUS$197,80002 Aug 19
Timothy Mayleben
Entity
Individual
Role
Chief Executive Officer
President
Shares
5,000
Max Price
US$39.56
BuyUS$2,132,56525 Jul 19
Bellevue Asset Management AG
Entity
Company
Shares
50,000
Max Price
US$42.65
BuyUS$230,00001 Jul 19
Timothy Mayleben
Entity
Individual
Role
Chief Executive Officer
President
Shares
5,000
Max Price
US$46.00
BuyUS$200,00001 Apr 19
Timothy Mayleben
Entity
Individual
Role
Chief Executive Officer
President
Shares
5,000
Max Price
US$40.00
BuyUS$217,40021 Mar 19
Timothy Mayleben
Entity
Individual
Role
Chief Executive Officer
President
Shares
5,000
Max Price
US$43.48
SellUS$76,92521 Mar 19
Domain Associates, L.L.C.
Entity
Company
Shares
1,700
Max Price
US$45.25
SellUS$608,67121 Mar 19
Domain Associates, L.L.C.
Entity
Company
Shares
13,629
Max Price
US$44.66
BuyUS$2,494,35515 Mar 19
Bellevue Asset Management AG
Entity
Company
Shares
50,000
Max Price
US$49.89
BuyUS$243,65014 Mar 19
Timothy Mayleben
Entity
Individual
Role
Chief Executive Officer
President
Shares
5,000
Max Price
US$48.73
BuyUS$3,303,25607 Jan 19
Bellevue Asset Management AG
Entity
Company
Shares
80,000
Max Price
US$41.29
BuyUS$1,995,72526 Dec 18
Bellevue Asset Management AG
Entity
Company
Shares
50,000
Max Price
US$39.91
BuyUS$2,864,07019 Dec 18
Bellevue Asset Management AG
Entity
Company
Shares
60,000
Max Price
US$47.73
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Tim Mayleben (58yo)
President
Tenure: 7yrs
Compensation: US$9.72m
Ken Fiorelli
Senior Vice President of Technical Operations
Tenure: 0.3yrs
Keith Lenden (46yo)
Vice President of Corporate Development & Strategy
Tenure: 0yrs
Bill Sasiela (53yo)
Senior Vice President of Clinical Development
Tenure: 1.7yrs
Mark Glickman (53yo)
Chief Commercial Officer
Tenure: 1.7yrs
Compensation: US$9.12m
Regina Cavaliere
Chief Ethics & Compliance Officer
Tenure: 0.4yrs
Rick Bartram (37yo)
CFO & Corporate Secretary
Tenure: 1.9yrs
Compensation: US$2.54m
Ashley Hall
Chief Development Officer
Tenure: 1.7yrs
Alex Schwartz
Senior Director of Investor Relations
Tenure: 1.6yrs
Renee Marotta
Head of Marketing
Tenure: 0yrs
Board Members
Dan Janney (54yo)
Independent Director
Tenure: 7.1yrs
Compensation: US$270.58k
Nicole Vitullo (62yo)
Lead Independent Director
Tenure: 4yrs
Compensation: US$311.66k
Tim Mayleben (58yo)
President
Tenure: 7yrs
Compensation: US$9.72m
Antonio Gotto (84yo)
Independent Director
Tenure: 5.9yrs
Compensation: US$290.84k
Jay Shepard (61yo)
Independent Director
Tenure: 1.6yrs
Compensation: US$477.34k
Jeff Berkowitz (53yo)
Director
Tenure: 2yrs
Compensation: US$1.41m
Tracy Woody (49yo)
Director
Tenure: 0.6yrs
Scott Braunstein (56yo)
Independent Director
Tenure: 4.5yrs
Compensation: US$305.63k
Mark McGovern (66yo)
Independent Director
Tenure: 5.8yrs
Compensation: US$287.35k
Company Information
Esperion Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). It ...
Company Analysis and Financial Data Status
All financial data provided by Standard & Poor's Capital IQ.
Data
Last Updated (UTC time)
Company Analysis
2019/12/13 00:50
End of Day Share Price
2019/12/12 00:00
Earnings
2019/09/30
Annual Earnings
2018/12/31
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.